BRIEF-Anavex Life Sciences Announces Positive Precision Medicine Results From Up To 4-Years Of Oral Blarcamesine Treatment In Phase Iib/Iii Open-Label Extension Trial In Early Alzheimer’S Disease

Reuters

Jul 31, 2025

BRIEF-<a href="https://laohu8.com/S/AVXL">Anavex Life</a> Sciences Announces Positive Precision Medicine Results From Up To 4-Years Of Oral Blarcamesine Treatment In Phase Iib/Iii Open-Label Extension Trial In Early Alzheimer’S Disease

July 31 (Reuters) - Anavex Life Sciences Corp AVXL.O:

ANAVEX LIFE SCIENCES ANNOUNCES POSITIVE PRECISION MEDICINE RESULTS FROM UP TO 4-YEARS OF ORAL BLARCAMESINE TREATMENT IN PHASE IIB/III OPEN-LABEL EXTENSION TRIAL IN EARLY ALZHEIMER’S DISEASE

Source text: ID:nGNX3kJ40z

Further company coverage: AVXL.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2555386248"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555386248\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555386248?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555386248","market":"us","top_or_hot":-1,"title":"BRIEF-Anavex Life Sciences Announces Positive Precision Medicine Results From Up To 4-Years Of Oral Blarcamesine Treatment In Phase Iib/Iii Open-Label Extension Trial In Early Alzheimer’S Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/AVXL\">Anavex Life</a> Sciences Announces Positive Precision Medicine Results From Up To 4-Years Of Oral Blarcamesine Treatment In Phase Iib/Iii Open-Label Extension Trial In Early Alzheimer’S Disease</title></head><body><p><span>July 31 (Reuters)</span><span> - </span>Anavex Life Sciences Corp <span>AVXL.O</span>:</p><ul><li><p>ANAVEX LIFE SCIENCES ANNOUNCES POSITIVE PRECISION MEDICINE RESULTS FROM UP TO 4-YEARS OF ORAL BLARCAMESINE TREATMENT IN PHASE IIB/III OPEN-LABEL EXTENSION TRIAL IN EARLY ALZHEIMER’S DISEASE</p></li></ul><p>Source text: <span>ID:nGNX3kJ40z</span></p><p>Further company coverage: <span>AVXL.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Anavex Life Sciences Announces Positive Precision Medicine Results From Up To 4-Years Of Oral Blarcamesine Treatment In Phase Iib/Iii Open-Label Extension Trial In Early Alzheimer’S Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Anavex Life Sciences Announces Positive Precision Medicine Results From Up To 4-Years Of Oral Blarcamesine Treatment In Phase Iib/Iii Open-Label Extension Trial In Early Alzheimer’S Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-31 20:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/AVXL\">Anavex Life</a> Sciences Announces Positive Precision Medicine Results From Up To 4-Years Of Oral Blarcamesine Treatment In Phase Iib/Iii Open-Label Extension Trial In Early Alzheimer’S Disease</title></head><body><p><span>July 31 (Reuters)</span><span> - </span>Anavex Life Sciences Corp <span>AVXL.O</span>:</p><ul><li><p>ANAVEX LIFE SCIENCES ANNOUNCES POSITIVE PRECISION MEDICINE RESULTS FROM UP TO 4-YEARS OF ORAL BLARCAMESINE TREATMENT IN PHASE IIB/III OPEN-LABEL EXTENSION TRIAL IN EARLY ALZHEIMER’S DISEASE</p></li></ul><p>Source text: <span>ID:nGNX3kJ40z</span></p><p>Further company coverage: <span>AVXL.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVXL","symbol_name":"Anavex Life Sciences Corp.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nTUA4WVXXC:1","article_id":"2555386248","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555386248","pubTimestamp":1753964119,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Anavex Life Sciences Announces Positive Precision Medicine Results From Up To 4-Years Of Oral Blarcamesine Treatment In Phase Iib/Iii Open-Label Extension Trial In Early Alzheimer’S DiseaseJuly ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVXL":"Anavex Life Sciences Corp.","BK4139":"生物科技"},"translate_title":"BRIEF-Anavex Life Sciences宣布在早期阿尔茨海默病的Iib/Iii期开放标签扩展试验中口服Blarcamesine治疗长达4年的精准医疗结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVXL":0.9},"content_text":"BRIEF-Anavex Life Sciences Announces Positive Precision Medicine Results From Up To 4-Years Of Oral Blarcamesine Treatment In Phase Iib/Iii Open-Label Extension Trial In Early Alzheimer’S DiseaseJuly 31 (Reuters) - Anavex Life Sciences Corp AVXL.O:ANAVEX LIFE SCIENCES ANNOUNCES POSITIVE PRECISION MEDICINE RESULTS FROM UP TO 4-YEARS OF ORAL BLARCAMESINE TREATMENT IN PHASE IIB/III OPEN-LABEL EXTENSION TRIAL IN EARLY ALZHEIMER’S DISEASESource text: ID:nGNX3kJ40zFurther company coverage: AVXL.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}